Send to

Choose Destination
Best Pract Res Clin Haematol. 2012 Sep;25(3):319-32. doi: 10.1016/j.beha.2012.07.006. Epub 2012 Aug 19.

Venous thromboembolism associated with pregnancy and hormonal therapy.

Author information

Oslo University Hospital Ullevål, Department of Obstetrics and Gynaecology, Oslo, Norway.


Venous thromboembolism (VTE) is a major cause of maternal morbidity and mortality during or early after pregnancy and in women taking hormonal therapy for contraception or for replacement therapy. Post-thrombotic syndrome, including leg oedema and leg pain, is an unrecognized burden after pregnancy-related VTE, which will affect more than two of five women. Women with a prior VTE, a family history of VTE, certain clinical risk factors and thrombophilia are at considerably increased risk both for pregnancy-related VTE and for VTE on hormonal therapy. This review critically assesses the epidemiology and risk factors for pregnancy-related VTE and current guidelines for prophylaxis and treatment. We also provide information on the risk of VTE related to hormonal contraception and replacement therapy.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center